Memorial Sloan Kettering Cancer Center

In a study of RCC patients on clinical trials using TM, 67% preferred in-person care, 64% found TM equal in quality, and 97% had positive/neutral TM experiences. Providers preferred in-person visits and rated TM quality lower, yet most had positive TM experiences. Further evaluation is needed for TM integration in clinical trial care.

Roswell Park CEO Candace Johnson introduces Michael Wong as the center's first Physician in Chief, aiming to enhance patient care and outcomes. Wong, a former MD Anderson Cancer Center professor, will lead clinical teams and focus on improving care delivery.

Healio Dermatology's top story in November focused on the CMS's 2025 physician fee schedule cuts and their impact on patient access, with FDA approvals for Emrosi, Bimzelx, and Microlyte Ag/Lidocaine also making headlines.

The 'Nuclear Imaging Equipment Pipeline Report, 2024 Update' provides comprehensive details on pipeline products, clinical trials, and key companies involved in nuclear imaging equipment development, aiding strategic R&D, market entry, and mergers and acquisitions.

Vorasidenib showed significant improvements in progression-free survival (PFS) and tumor shrinkage in patients with IDH1/2-mutated diffuse glioma, with a 65% reduction in disease progression risk compared to placebo, according to the phase 3 INDIGO trial. The study also confirmed better seizure control and a reduction in tumor volume with vorasidenib, with no additional safety concerns observed.

Precision medicine and biomarker testing are reshaping breast cancer treatment, with Dr. Maria Theodoulou discussing challenges in HR+/HER2- metastatic breast cancer and potential advances to redefine treatment paradigms.

Jhalene Mundin, a 35-year-old non-smoker, was diagnosed with stage 4 non-small cell lung cancer in 2023, which led her to Memorial Sloan Kettering Cancer Center. Under the care of Dr. Alexander Drilon, her tumors shrank enough for surgical removal, and she now receives chemotherapy to prevent recurrence. Lung cancer is increasingly common in women and never-smokers, with 20% of cases in never-smokers. Jhalene's tumor had an EGFR mutation, common in younger women, for which targeted therapies are available. Her quick access to MSK's clinical trials and supportive care contributed to her successful treatment and recovery.

Two-thirds of patients with PI3K-mutant brain metastases responded to paxalisib plus radiation therapy, with 8/12 having intracranial responses. TTFields therapy improved median progression-free survival in glioblastoma from 5.6 to 9.9 months. Proton craniospinal irradiation showed a median overall survival of 13.7 months for leptomeningeal metastases.

Clinical trials for mesothelioma offer new treatment options, including SMARTEST (radiation before surgery, immunotherapy after), intraperitoneal chemotherapy post-surgery, combination chemotherapy and immunotherapy, and immunotherapy with chemotherapy for peritoneal mesothelioma.

Vorasidenib maintained twice the progression-free survival (PFS) in IDH-mutant low-grade glioma patients post-surgery compared to placebo, with a 65% reduction in the hazard for disease progression or death. Median PFS and time to next intervention (TTNI) were not estimable with vorasidenib versus 11.4 months and 20.1 months for placebo, respectively. Vorasidenib showed robust efficacy, manageable safety, and better seizure control, reducing tumor volume and causing shrinkage.